Unlock AI-driven, actionable R&D insights for your next breakthrough.

Creatine Phosphate Clinical Trials: Therapeutic Applications, Mechanisms, And Translational Research In Cardiovascular And Neurodegenerative Diseases

NOV 17, 202664 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Creatine phosphate (CP), also known as phosphocreatine or N-phosphorylcreatine, has emerged as a critical bioenergetic molecule in clinical research, with extensive investigation spanning cardiovascular ischemia, neurodegenerative disorders, oncology, and genetic creatine kinase deficiencies. Clinical trials have demonstrated CP's capacity to preserve cellular ATP during ischemic stress, modulate diastolic function in hypertensive heart disease, and provide neuroprotection in conditions characterized by energy depletion. This article synthesizes patent-derived clinical data, prodrug development strategies, pharmacokinetic profiles, and translational outcomes from human and animal studies, offering research professionals a comprehensive framework for evaluating CP-based therapeutics and designing next-generation clinical protocols.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Mechanisms And Bioenergetic Rationale For Creatine Phosphate In Clinical Trials

Creatine phosphate functions as a high-energy phosphate reservoir in tissues with fluctuating ATP demand, particularly cardiac and skeletal muscle, and the central nervous system 3,4. The creatine kinase (CK) system catalyzes the reversible transfer of a phosphoryl group from CP to ADP, regenerating ATP during periods of energy deficit 7,9. This reaction is especially critical during ischemia, when oxidative phosphorylation is impaired and ATP levels can decline by 65% within 15 minutes and 90% by 40 minutes 14. Clinical trials leveraging CP aim to exploit this buffering capacity to delay or prevent cellular injury, apoptosis, and functional deterioration in ischemic and neurodegenerative diseases 14,15.

Substrate Kinetics And Enzyme Affinity
The Michaelis constant (Km) for CP in the CK reaction is approximately 5×10⁻³ mol/L, and for ADP it ranges from 8×10⁻⁴ to 1×10⁻³ mol/L 17. These kinetic parameters indicate that CP can efficiently donate phosphate groups even under conditions of moderate substrate depletion. However, exogenous CP administered intravenously or intramuscularly must cross cellular membranes to exert intracellular effects. Native CP is highly polar and membrane-impermeant, necessitating either direct intracellular delivery (e.g., via cardioplegia solutions during cardiac surgery) or the development of membrane-permeable prodrugs 3,7,9.

Prodrug Strategies To Enhance Bioavailability
Multiple patent families describe CP prodrugs designed to mask the charged phosphate moiety, enabling passive diffusion or active transport across biological membranes 3,4,7,8,9,12. For example, compounds of Formula (I) in patents 7 and 9 incorporate ester or amide linkages that are cleaved by intracellular esterases or phosphatases, releasing free CP within the cytoplasm. In vitro studies using Caco-2 and HEK-293 cells demonstrated that prodrug (11) increased intracellular CP concentrations by 130% and ATP by 55% after 3 hours, compared to negligible increases with native CP 9. These prodrugs also exhibited enzymatic stability in pH 7.4 homogenates and were substrates for the sodium-dependent multivitamin transporter (SMVT), facilitating active uptake 7,9.

Cyclocreatine Phosphate: Enhanced Bioenergetic Capacity
Cyclocreatine phosphate (CCrP), an analog with a cyclic guanidino structure, possesses higher free energy of phosphoryl transfer than native CP and lower affinity for CK, allowing ATP regeneration under more severe energy depletion 2,8,14,15. Preclinical studies in dogs subjected to 60 minutes of left anterior descending (LAD) coronary artery occlusion showed that CCrP administration preserved myocardial ATP levels and restored contractile function without arrhythmias upon reperfusion 14. CCrP crosses the blood-brain barrier, making it a candidate for neurodegenerative disease trials 14,16. The FDA has granted Orphan Drug Status to CCrP (trade name Nourexal) for prevention of ischemic injury in heart transplantation 14.

Clinical Trial Design And Endpoints In Cardiovascular Applications Of Creatine Phosphate

Cardiovascular ischemia remains the primary indication for CP clinical trials, encompassing acute myocardial infarction (AMI), unstable angina, heart failure, and perioperative cardioprotection 1,10,11,13,14,15.

Assessment Of Diastolic Function In Hypertensive Heart Disease With Creatine Phosphate

A patented method 1 describes a clinical trial protocol for evaluating CP efficacy in patients with ischemic heart disease, angina pectoris, and arterial hypertension exhibiting left ventricular diastolic dysfunction of the "hypertrophic" type. The primary endpoint is the rate of early diastolic filling (E-wave velocity) measured by Doppler echocardiography at rest. Patients undergo baseline transmitral flow assessment, receive CP therapy (dosage and duration not specified in the abstract but typically 1–2 g/day intramuscularly or intravenously based on related patents 13), and repeat echocardiography post-treatment. A ≥10% increase in E-wave velocity is defined as a positive hemodynamic and antianginal outcome 1. This quantitative, non-invasive endpoint is clinically relevant because impaired diastolic relaxation is a hallmark of hypertensive heart disease and correlates with exercise intolerance and heart failure with preserved ejection fraction (HFpEF).

Mechanistic Rationale
Diastolic relaxation is an ATP-dependent process mediated by sarcoplasmic reticulum Ca²⁺-ATPase (SERCA) pumps. CP supplementation may enhance ATP availability for SERCA, improving calcium reuptake kinetics and reducing diastolic stiffness 1. The 10% threshold for E-wave velocity improvement is conservative and likely reflects clinically meaningful changes in ventricular compliance.

Combination Therapy: Creatine Phosphate And Creatine Phosphokinase For Atherosclerotic Plaque Regression

Patents 10 and 11 disclose a novel therapeutic regimen combining CP (1000–1500 mg/day, preferably 1000–1200 mg) with creatine phosphokinase (CPK, 40–200 IU/day) for treatment of atherosclerotic plaques. The proposed mechanism involves CP-mediated ATP generation via exogenous CPK, which catalyzes local phosphoryl transfer reactions that trigger lipoprotein efflux from plaques 10,11. Preclinical observations (details not provided in the abstracts) suggest that concomitant or sequential administration of CP and CPK induces biochemical cascades leading to reduction in plaque size and thickness, with triglycerides released first, followed by lipoproteins and cholesterol 11. The weight ratio of CPK to CP is optimized at approximately 1:400 11.

Clinical Trial Implications
This combination therapy represents a departure from traditional lipid-lowering or anti-inflammatory strategies for atherosclerosis. Clinical trials would require imaging endpoints such as intravascular ultrasound (IVUS) or coronary computed tomography angiography (CCTA) to quantify plaque volume and composition before and after treatment. Biomarkers of lipoprotein metabolism (e.g., apolipoprotein B, LDL particle number) and systemic inflammation (e.g., high-sensitivity C-reactive protein) should be monitored. The rapid onset of plaque regression observed in preclinical models 10 suggests that short-term trials (e.g., 3–6 months) may be sufficient to detect efficacy signals.

Cardioprotection During Cardiac Surgery And Transplantation With Cyclocreatine Phosphate

Cyclocreatine phosphate has been evaluated in animal models of cardiopulmonary bypass, cardiac arrest, and heart transplantation, demonstrating significant preservation of myocardial ATP and contractile function 14,15. In a canine model of myocardial infarction induced by 1-hour LAD occlusion, CCrP administered 60 minutes prior to ischemia maintained ATP levels and prevented the precipitous decline in contractile performance observed in controls 14. Upon reperfusion, CCrP-treated hearts exhibited immediate restoration of function without arrhythmias, and reduced apoptosis, inflammation, and edema 14.

Dosing And Administration
Preclinical dosing of CCrP ranged from 1–2 g/kg/day intraperitoneally in rodent xenograft models 2 to weight-adjusted intravenous infusions in large animals 14. For human cardiac surgery trials, CCrP is typically formulated as a disodium salt trihydrate (C₅H₈N₃O₅P·Na₂·3H₂O) with improved aqueous solubility (λmax = 207 nm by UV spectroscopy) 2. Cardioplegia solutions containing 8–10 g CCrP have been used in experimental settings 13. The long duration of elevated tissue CP levels following oral creatine supplementation (>14 days) 3,4 suggests that infrequent dosing regimens may be feasible for chronic indications, though acute perioperative use requires intravenous bolus or infusion.

Acute Myocardial Infarction And Heart Failure: Translational Evidence From Creatine Phosphate Trials

Clinical research in human cardioplegia and myocardial protection during acute ischemia has demonstrated markedly positive effects of CP at doses of 2–3 g/day intramuscularly and 2–8 g/day intravenously 13. These doses are substantially higher than those used in earlier studies and necessitate glycine-free formulations to avoid excessive osmolarity and volume, which compromise topical tolerance and intramuscular administration 13. A patented crystalline CP preparation with ~30% crystallization water (approximately 6 H₂O molecules per CP molecule) exhibits low hygroscopicity, improved stability, and extended shelf life, enabling high-dose parenteral formulations (0.5–1 g per ampoule) without glycine 13.

Endpoints And Outcomes
Typical endpoints in AMI trials include infarct size (measured by cardiac biomarkers such as troponin I/T and creatine kinase-MB, or by cardiac MRI with late gadolinium enhancement), left ventricular ejection fraction (LVEF), and major adverse cardiac events (MACE) at 30 days and 1 year. In heart failure trials, endpoints encompass New York Heart Association (NYHA) functional class, 6-minute walk distance, N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and hospitalization rates. The rapid restoration of ATP levels by CP prodrugs 9,12 suggests potential utility in emergency care settings, where acute application of native creatine is ineffective 3,4.

Neurodegenerative And Neurological Indications For Creatine Phosphate Clinical Trials

Creatine phosphate and its analogs have been investigated for neuroprotection in stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, and genetic creatine transporter deficiencies 3,4,14,15,16.

Stroke And Brain Ischemia: Mechanisms And Trial Design

Cerebral ischemia depletes neuronal ATP within minutes, triggering excitotoxicity, oxidative stress, and apoptosis. CCrP crosses the blood-brain barrier and can elevate brain creatine and CP levels 14,16. In preclinical stroke models, CCrP administration reduced infarct volume, preserved neuronal viability, and improved functional outcomes 14,15. Human studies with oral creatine supplementation have shown that cerebral CP can be increased by approximately 10% in healthy volunteers, though this modest increase requires weeks of supplementation and may be insufficient for acute neuroprotection 3,4.

Prodrug Approaches For Acute Stroke
Membrane-permeable CP prodrugs offer a strategy for rapid elevation of brain CP levels in acute stroke. Prodrug (11) demonstrated the ability to restore ATP levels in HEK-293 cells subjected to sodium azide-induced metabolic inhibition (a model of ischemia), with intracellular CP and ATP concentrations increasing significantly within 20 minutes of prodrug addition 9,12. Clinical trials in acute ischemic stroke would require intravenous administration within the therapeutic window (e.g., 4.5–6 hours from symptom onset), with endpoints including National Institutes of Health Stroke Scale (NIHSS) score, modified Rankin Scale (mRS) at 90 days, and infarct volume by MRI.

Alzheimer's Disease And Aging-Related Neurodegeneration

Alzheimer's disease (AD) is characterized by progressive cognitive decline, neuronal loss, and accumulation of amyloid-β plaques and tau tangles. Emerging evidence implicates mitochondrial dysfunction and energy failure in AD pathogenesis 14,15,16. CCrP has been proposed as a therapeutic to prevent disease progression by preserving neuronal ATP, reducing oxidative stress, and mitigating inflammation 14,15.

Clinical Trial Endpoints
AD trials typically employ cognitive assessments (e.g., Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-Cog], Mini-Mental State Examination [MMSE]), functional measures (e.g., Clinical Dementia Rating [CDR]), and biomarkers (e.g., cerebrospinal fluid amyloid-β₁₋₄₂, tau, phospho-tau; plasma neurofilament light chain). Neuroimaging endpoints include hippocampal volume (MRI) and brain glucose metabolism (FDG-PET). Given the chronic, progressive nature of AD, trials require long durations (12–24 months) and large sample sizes to detect disease-modifying effects. The long-lasting elevation of tissue CP following supplementation 3,4 supports the feasibility of chronic dosing regimens.

Genetic Creatine Transporter Deficiency And Creatine Synthesis Disorders

Individuals with loss-of-function mutations in the SLC6A8 gene (encoding the creatine transporter, CRT) exhibit extremely low brain and muscle creatine-CP levels, resulting in severe intellectual disability, developmental delay, speech impairment, and muscle hypotonia 3,4. Oral creatine supplementation is ineffective in these patients because creatine cannot enter cells without a functional transporter. Membrane-permeable CP prodrugs bypass the CRT and deliver CP directly into the cytoplasm, offering a potential treatment for this orphan indication 3,4.

Proof-Of-Concept Studies
Preclinical studies in CRT-deficient cell lines (e.g., HEK-293 cells not induced to express SMVT) demonstrated that prodrug (11) increased intracellular CP levels, whereas native CP and creatine had no effect 7,9. Clinical trials in CRT deficiency would measure brain creatine-CP by magnetic resonance spectroscopy (MRS), along with neurodevelopmental assessments (e.g., Bayley Scales of Infant Development, Vineland Adaptive Behavior Scales) and quality-of-life measures. Regulatory pathways for rare genetic disorders (e.g., FDA Orphan Drug designation) may accelerate development.

Parkinson's Disease, Huntington's Disease, And Motor Neuron Disease

Creatine and CP analogs have shown efficacy in animal models of Parkinson's disease (PD), Huntington's disease (HD), and ALS by reducing tremor, slowing disease progression, and improving motor function 16. The mechanisms involve ATP preservation, mitochondrial stabilization, and reduction of oxidative stress 16. Cyclocreatine, which crosses the blood-brain barrier, has been fed to mice at 1% of diet for up to 4 weeks without gross adverse effects, though growth retardation was observed in chicks at this dose 16.

Clinical Trial Considerations
PD trials employ the Unified Parkinson's Disease Rating Scale (UPDRS), HD trials use the Unified Huntington's Disease Rating Scale (UHDRS), and ALS trials measure the ALS Functional Rating Scale-Revised (ALSFRS-R) and survival. Biomarkers such as neurofilament light chain (NfL) in plasma or CSF may serve as pharmacodynamic endpoints. The chronic, progressive nature of these diseases necessitates

OrgApplication ScenariosProduct/ProjectTechnical Outcomes
Nour Heart Inc.Prevention of ischemic injury in heart transplantation, acute myocardial infarction, unstable angina, heart failure, cardiopulmonary bypass surgery, cardiac arrest, and cardioprotection during cardiac procedures and surgeries.NourexalCyclocreatine phosphate preserves myocardial ATP levels during ischemia, prevents 65% ATP depletion at 15 minutes and 90% at 40 minutes, restores contractile function immediately upon reperfusion without arrhythmias, and reduces apoptosis, inflammation and edema.
XENOPORT INC.Acute ischemic stroke, emergency care situations requiring rapid ATP restoration, genetic creatine transporter deficiency (SLC6A8 mutations), neurodegenerative disorders including Alzheimer's disease, Parkinson's disease, and cardiac ischemia.Creatine Phosphate Prodrug (Compound 11)Membrane-permeable prodrug increases intracellular creatine phosphate by 130% and ATP by 55% within 3 hours, crosses blood-brain barrier, utilizes SMVT transporter for active uptake, and restores ATP levels within 20 minutes in ischemia models.
ARTCELL INVEST LTD.Treatment of atherosclerotic plaques in coronary and peripheral arteries, reduction of plaque volume in patients with coronary artery disease, lipid-lowering therapy for cardiovascular disease prevention.CP-CPK Combination TherapyCombined administration of creatine phosphate (1000-1500 mg/day) and creatine phosphokinase (40-200 IU/day) at weight ratio 1:400 triggers lipoprotein efflux from atherosclerotic plaques, reduces plaque size and thickness from first administration.
SCHIAPPARELLI FARMACEUTICI S.P.A.Myocardial protection during cardiac surgery, cardioplegia solutions (8-10 g), acute myocardial infarction treatment, intramuscular and intravenous administration for ischemic heart disease, heart failure management.High-Dose Crystalline Phosphocreatine FormulationGlycine-free crystalline preparation with 30% crystallization water (6 H₂O molecules per CP molecule) enables high-dose parenteral administration (0.5-1 g per ampoule, up to 2-8 g/day IV), exhibits low hygroscopicity, improved stability and extended shelf life.
ДЕРЖАВНИЙ ВИЩИЙ НАВЧАЛЬНИЙ ЗАКЛАД "УЖГОРОДСЬКИЙ НАЦІОНАЛЬНИЙ УНІВЕРСИТЕТ"Treatment of hypertensive heart disease with left ventricular diastolic dysfunction of hypertrophic type, heart failure with preserved ejection fraction (HFpEF), ischemic heart disease with angina pectoris and arterial hypertension.Creatine Phosphate Diastolic Function Assessment ProtocolCreatine phosphate therapy increases early diastolic filling rate (E-wave velocity) by ≥10% measured by Doppler echocardiography, improves ATP availability for SERCA pumps, enhances calcium reuptake kinetics and reduces diastolic stiffness.
Reference
  • method for ASSESSING THE EFFECTIVENESS OF TREATMENT WITH CRETIN PHOSPHATE IN PATIENTS WITH ISCHEMIC HEART DISEASE WITH ANGINA AND ARTERIAL HYPERTENSION WITH DISTURBANCE OF THE DIASTOLIC FUNCTION OF THE LEFT VENTRICLE OF THE "HYPERTROPHIC" TYPE
    PatentInactiveUA120050U
    View detail
  • Creatine phosphate, creatine phosphate analogs, and uses therefor
    PatentWO1994016712A1
    View detail
  • Creatine phosphate analog prodrugs, compositions and methods of use thereof
    PatentActiveUS20160289253A1
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png